Lilly Compound X (LCX) is an oncology drug that was tested in a phase I clinical study using starch blend capsules. The drug showed large inter- and intra-patient variability due to variations in stomach acidity and other factors.
Faraj Atassi and colleagues, Lilly Research Labs, Indianapolis, USA, conducted artificial stomach−duodenum (ASD) experiments to investigate the hypothesis that carefully selected dosing fluids would have an impact in minimizing exposure variability caused by the formulation.
Administrating Compound X with Captisol, a substance that helps improve the solubility of drug ingredients, along with Sprite was shown by the ADS to control stomach acidity in a way likely to allow optimal absorption of the drug into the body. Based on the results, the scientists suggest that patients in future clinical trials take the drug with Sprite.
Photo: (C) PhotoDisc, Inc./Getty Images
- Use of Artificial Stomach−Duodenum Model for Investigation of Dosing Fluid Effect on Clinical Trial Variability,
Christopher S. Polster, Faraj Atassi, Sy-Juen Wu, and David C. Sperry;
Mol. Pharmaceutics 2010, 7 (5), 533–1538.